After the fantastic news of this weekend "CRISPR-Cas9 gene editing successful for a patient with Sickle Cell Disease and another patient with transfusion dependent β-Thalassemia - More than a year later, both patients had clinically improved and no longer needed blood transfusions. (NEJM, 5 Dec 2020)" all CRISPR stocks booked new ATH's with the exception of EDITAS medicine which is at a 52week high. Early innings for a Trillion dollar market...
$CRSP ATH:
https://www.reddit.com/r/CrisprTherapeutics/comments/k8pmvo/crsp_at_ath_071220/
$NTLA ATH:
https://www.reddit.com/r/IntelliaTherapeutics/comments/k8pl2p/ntla_at_ath_071220/
$BEAM ATH:
https://www.reddit.com/r/BeamTherapeutics/comments/k8pq62/beam_at_ath_071220/
$EDIT 52week high:
https://www.reddit.com/r/EditasMedicine/comments/k8pjsw/edit_at_52week_high/
Introduction to CRISPR:
Video: https://www.youtube.com/watch?v=jAhjPd4uNFY&ab_channel=Kurzgesagt%E2%80%93InaNutshell
Article I posted on wsb 6 months ago: https://www.reddit.com/r/wallstreetbets/comments/gk6up7/crispr_introduction_ntla_crsp_edit_beam/
Submitted December 07, 2020 at 04:46PM by Anonymous-Green https://ift.tt/3mW33Zr